Literature DB >> 28187279

Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection.

Alexander M Aravanis1, Mark Lee1, Richard D Klausner2.   

Abstract

Curative therapies are most successful when cancer is diagnosed and treated at an early stage. We advocate that technological advances in next-generation sequencing of circulating, tumor-derived nucleic acids hold promise for addressing the challenge of developing safe and effective cancer screening tests.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28187279     DOI: 10.1016/j.cell.2017.01.030

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  105 in total

1.  [Genetic risk factors for a second neoplasm in children who have survived a first malignant disease].

Authors:  Martin G Sauer
Journal:  Strahlenther Onkol       Date:  2019-02       Impact factor: 3.621

2.  Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses.

Authors:  C Abbosh; C Swanton; N J Birkbak
Journal:  Ann Oncol       Date:  2019-03-01       Impact factor: 32.976

Review 3.  Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.

Authors:  Shreya Sengupta; Neehar D Parikh
Journal:  Hepat Oncol       Date:  2017-11-17

4.  Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.

Authors:  Zhaoming Wang; Carmen L Wilson; John Easton; Andrew Thrasher; Heather Mulder; Qi Liu; Dale J Hedges; Shuoguo Wang; Michael C Rusch; Michael N Edmonson; Shawn Levy; Jennifer Q Lanctot; Eric Caron; Kyla Shelton; Kelsey Currie; Matthew Lear; Aman Patel; Celeste Rosencrance; Ying Shao; Bhavin Vadodaria; Donald Yergeau; Yadav Sapkota; Russell J Brooke; Wonjong Moon; Evadnie Rampersaud; Xiaotu Ma; Ti-Cheng Chang; Stephen V Rice; Cynthia Pepper; Xin Zhou; Xiang Chen; Wenan Chen; Angela Jones; Braden Boone; Matthew J Ehrhardt; Matthew J Krasin; Rebecca M Howell; Nicholas S Phillips; Courtney Lewis; Deokumar Srivastava; Ching-Hon Pui; Chimene A Kesserwan; Gang Wu; Kim E Nichols; James R Downing; Melissa M Hudson; Yutaka Yasui; Leslie L Robison; Jinghui Zhang
Journal:  J Clin Oncol       Date:  2018-05-30       Impact factor: 44.544

Review 5.  Molecular mechanisms of the preventable causes of cancer in the United States.

Authors:  Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins
Journal:  Genes Dev       Date:  2018-06-26       Impact factor: 11.361

Review 6.  Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations.

Authors:  Jesse J Salk; Michael W Schmitt; Lawrence A Loeb
Journal:  Nat Rev Genet       Date:  2018-03-26       Impact factor: 53.242

7.  Clinical testing should be individualized, not based on populations.

Authors:  David R Walt
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

8.  State of the Science and Future Directions for Liquid Biopsies in Drug Development.

Authors:  Preeti Narayan; Soma Ghosh; Reena Philip; J Carl Barrett; Robert T McCormack; Justin I Odegaard; Geoffrey R Oxnard; Laurel J Pracht; P Mickey Williams; Gary J Kelloff; Julia A Beaver
Journal:  Oncologist       Date:  2020-06-29

9.  Ultraspecific and Amplification-Free Quantification of Mutant DNA by Single-Molecule Kinetic Fingerprinting.

Authors:  Stephen L Hayward; Paul E Lund; Qing Kang; Alexander Johnson-Buck; Muneesh Tewari; Nils G Walter
Journal:  J Am Chem Soc       Date:  2018-09-05       Impact factor: 15.419

10.  CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy.

Authors:  Rachel L Mintz; Madeleine A Gao; Kahmun Lo; Yeh-Hsing Lao; Mingqiang Li; Kam W Leong
Journal:  Adv Biosyst       Date:  2018-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.